The FDA panel’s unanimous recommendation to approve an autologous leukemia treatment represents a paradigm shift in medicine in which gene therapies and stem cells will play leading roles.
The treatment involves altering the genes of T cells, which are highly specialized stem cells obtained from bone marrow, to target a specific protein on the surface of defective immune cells that cause leukemia. It works by harvesting the cells from the patient, engineering them to target the protein CD-19 on the surface of B Cells, and intravenously administering the cells back into the patient, where they multiply and essentially eradicate the B Cells. Showing promise, over 80% of the patients in the trial have gone into remission.
The treatment paves the way for other stem cell treatments involving more efficient methods of genetic engineering – such a CRISPR, to treat other devastating genetic disorders. It also highlights the role stem cells will play in these emerging treatments - taking advantage of the unique characteristic of stem cells to regenerate. Reprogramming stem cells enables the newly programmed cells to proliferate to clinically relevant numbers.
This latest medical breakthrough demonstrates the wisdom of banking stem cells. By banking their own valuable stem cells, families and individuals, can ensure that they will have access to these emerging therapies. To learn more about banking stem cells, please visit StemSave or call 877-783- 6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.